{"title":"National adaptation and implementation","nid":762,"vid":4280,"created":1622113119,"changed":1626693579,"field_accordian_header":[{"field_accordian":[{"field_title":"The choice of ACTs in a","field_content":"The choice of ACTs in a country or region should be based on optimal efficacy, safety and adherence.<br>\n&nbsp;\n<p class=\"statement\" style=\"background-color:rgb( 102 , 204 , 255 );  padding-left: 15px; padding-right: 15px; padding-top: 8px; padding-bottom: 5px;\"><span style=\"color:#0000cd\"><em>Good practice statement<\/em><\/span><\/p><\/tbody>\n","justification":null,"practical_info":"<p>Pharmacovigilance is the practice of monitoring the effects of medical drugs after they have been licensed for use, especially to identify and evaluate previously unreported adverse reactions. <a href=\"https:\/\/www.who.int\/malaria\/publications\/atoz\/9789241547499\/en\/\" target=\"_blank\" rel=\"noopener noreferrer\"><i>A practical handbook on the pharmacovigilance of antimalarial medicines<\/i><\/a><i>&nbsp;<\/i><cite class=\"magic-cite\" data-ref-id=\"362722\" data-label=\"\">[151]<\/cite>&nbsp;provides a step-by-step approach for antimalarial pharmacovigilance. Designed for health officials, planners, and other health workers, it focuses on active and passive pharmacovigilance, reporting, event monitoring and other key factors.&nbsp;<\/p>","field_icon":null}],"field_header":"The choice of ACTs in a"},{"field_accordian":[{"field_title":"Drugs used in IPTp, SMC and","field_content":"Drugs used in IPTp, SMC and IPTi should not be used as a component of first- line treatments in the same country or region.<br>\n&nbsp;\n<p class=\"statement\" style=\"background-color:rgb( 102 , 204 , 255 );  padding-left: 15px; padding-right: 15px; padding-top: 8px; padding-bottom: 5px;\"><span style=\"color:#0000cd\"><em>Good practice statement<\/em><\/span><\/p><\/tbody>\n","justification":null,"practical_info":null,"field_icon":null}],"field_header":"National adaptation and implementation&nbsp;(2015)"},{"field_accordian":[{"field_title":"When possible,","field_content":"When possible, use:\n<ul><li>fixed-dose combinations rather than co-blistered or loose, single-agent formulations; and<\/li><li>for young children and infants, paediatric formulations, with a preference for solid formulations (e.g. dispersible tablets) rather than liquid formulations.<\/li><\/ul>\n&nbsp;\n\n<p class=\"statement\" style=\"background-color:rgb( 102 , 204 , 255 );  padding-left: 15px; padding-right: 15px; padding-top: 8px; padding-bottom: 5px;\"><span style=\"color:#0000cd\"><em>Good practice statement<\/em><\/span><\/p><\/tbody>\n","justification":null,"practical_info":null,"field_icon":null}],"field_header":"National adaptation and implementation&nbsp;(2015)"}],"field_content_type":{"tid":9,"name":"Accord","class":"accord"},"field_left_right_navigation":1,"field_operational_":[{"field_image":"","field_link":"","field_title":null}],"field_recommendations":1,"recommendation":"<p>All cases of suspected malaria should have a parasitological test (microscopy or Rapid diagnostic test (RDT)) to confirm the diagnosis.<br \/>\r\nBoth microscopy and RDTs should be supported by a quality assurance programme.<br \/>\r\n<font color=\"#4090CF\"><em>Good practice statement<\/em><\/font><\/p>\r\n","recommendation_title":"Rapid diagnostic test (RDT)","field_recommendation_api_url":"https:\/\/api.magicapp.org\/api\/v1\/recommendations\/?sectionId=78118","field_references":null,"field_tags":[{"tid":66,"name":"Recommendations for case management"},{"tid":42,"name":"Drug efficacy & resistance"}]}